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Background: This study aimed to explore the role of apoptosis initiators, caspase-9, caspase-10, mitochondrial
anti-viral signaling protein (MAVS), and interferon regulatory factor 7 (pIRF7), in patients with systemic lupus
erythematosus (SLE).
Methods: Leukocyte apoptosis was determined by flow cytometry, including annexin V, APO2.7, and 7-amino-
actinomycin D (7-AAD) on each subtype of leukocyte in 35 patients with SLE, 15 disease controls, and 17 volunteer
normal controls. Levels of caspase-9, caspase-10, MAVS, and pIRF7 in mononuclear cells and the disease activity
index (SLEDAI) in the SLE patients were determined. Correlation among intracellular adaptor proteins and caspase
levels were calculated.
Results: The SLE patients had higher APO2.7 in total leukocyte, lymphocyte, and monocytes, and higher late
apoptosis markers in total leukocytes and neutrophils than normal controls (all p < 0.05). Disease activity was
positively associated with the APO2.7 of CD19+ cells in SLE, but negatively associated with MAVS and caspase-9
levels (all p < 0.05). Markers of viral infection and anti-virus transcription factors like MDA5, MAVS, and pIRF7 were
significantly higher in SLE patients than in disease controls (p < 0.05). Caspase-9 and caspase-10 levels positively
correlated with MAVS and pIRF7 in SLE patients (p < 0.05).
Conclusions: The disease activity of SLE is positively associated with APO2.7 level of CD19+ cells but negatively
associated with MAVS and caspase-9 levels, which all point to a mitochondrial pathway.
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Systemic lupus erythematosus (SLE) is a chronic systemic
disease affecting mostly women of child-bearing age. It is
the prototype of autoimmune diseases because of the
variety of its proposed pathogenesis, including apoptosis.
A previous study has demonstrated that lymphocyte apop-
tosis is increased and the removal of apoptotic cells is
impaired in SLE. Apoptosis is also higher in active SLE
compared to inactive SLE [1].* Correspondence: chlu99@ms44.url.com.tw
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unless otherwise stated.A recent study has demonstrated elevated apoptosis in
SLE patients [2] and a correlation between disease activity
and the apoptotic marker APO2.7 on CD19+ lympho-
cytes. Detection of APO2.7 apoptosis indicates that the
inner side of the outer membrane of the mitochondria is
turned over, which may be initiated by either an extrinsic
or intrinsic apoptotic process [3]. The external apoptotic
signal is executed through cell surface receptors (e.g.
TNFR1, FAS), whereas caspase-10 is activated through
proteolytic processes into several active isoforms (e.g.
active cleaved form) [3]. Caspase-9 is known either as an
initiator caspase of the mitochondrial intrinsic apoptotic
pathway or an adaptor of the dependent receptor of apop-
tosis (Figure 1) [3,4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pathways of cell death and the interactions between initiator caspases. This figure is mainly from the reference Cell Death Differ,
2012. 19(1): p. 107-20.
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(PBMCs) include both lymphocytes and monocytes. In
SLE patients, these two lineages of leukocytes are key
players of the disease pathogenesis. The apoptotic signa-
ture may be started from the bone marrow of SLE patients
[5]. Apoptosis and impaired apoptotic clearance are noted
in SLE patients and such impaired mechanisms are docu-
mented as a pathogenesis of SLE [6]. The major functions
of these two leukocyte lines are antigen presentation and
the execution of adaptive immunity and interferon pro-
duction against infection [7,8]. Aside from mononuclear
cells of leukocytes, viruses have a role in inducing lupus
and lupus flare-ups [9-12]. However, with the incorpor-
ation of the interferon pathway, the present study focuses
on interferon regulatory factor 7 (IRF7) and its related
protein in PBMCs, which have not been thoroughly
investigated.
The post-viral immune response should induce IRF
gene activation [13]. The change in IRF7 phosphorylation
levels may be explained by the aberrant activation of the
NLRP3 pathway [14], STAT1 pathway [15], or IRF3 [16]
downstream of the mitochondrial anti-viral signaling pro-
tein (MAVS) due to inflammation. On the other hand,
autoimmunity or the cytokine milieu in SLE may also be
causes [17-19].
To date, little clinical research has focused specifically
on the apoptosis pathway in SLE patients [20]. Because of
the possible benefits in choice of appropriate immuno-
suppressant regimens to reduce the degree of functional
morbidity, there is a need to further improve the under-
standing of the pathogenesis of leukocyte apoptosis. Hence,
this study explored the associations among caspases, phos-




Thirty-five patients with definitive diagnosis of SLE and
followed-up at the Rheumatology Out-patient Clinic for
more than six months were prospectively evaluated. The
diagnostic criteria for SLE were based on the 1997 revision
of the 1982 American College of Rheumatology (ACR)
classification criteria for SLE [21], while the clinical assess-
ment of SLE disease activity was based on the SLE disease
activity index (SLEDAI) [22]. All SLE patients were regu-
larly followed-up at the clinics for more than six months
to ensure that their conditions were stable and that their
steroid dose and immune-modifying medication were
not changed during the study period. For comparison,
18 age- and sex-matched healthy subjects were enrolled
as healthy controls. Fifteen patients with a diagnosis of
Sjogren’s syndrome, rheumatoid arthritis, vasculitis, or
Behcet’s disease were also included as disease control
patients.The Institutional Review Committee on Human Research
approved the study protocol and all of the participants pro-
vided informed consent. Patients were excluded if they had
autoimmune diseases other than SLE or if they had fever or
any infectious disorder that might affect the WBC count.
Clinical assessments
All of the subjects underwent complete medical examina-
tions upon enrollment. Complement levels and anti-double
strand DNA levels were done regularly and collected at the
same time upon enrollment. Biomarkers, including demo-
graphic data, complement levels, anti-ribosomal p autoanti-
body (a-rib p), and anti-double strand DNA autoantibody
(a-dsDNA) levels, and disease activity index, were also
collected. Since there were no clinical practice guidelines
for SLE flare-up, the important decision in immuno-sup-
pressant adjuvant treatment was whether or not to add a
cytotoxic or corticosteroid-sparing drug like cyclophos-
phamide, methotrexate, azathioprine, mycophenolate mo-
fetil, or leflunomide. The daily equivalent dose of steroids
and the number of corticosteroid-sparing drugs used by
SLE and disease control patients were recorded.
Blood sampling and assessment of leukocyte apoptosis
Blood samples were collected by venipuncture of forearm
veins of the SLE patients and controls.
Flow cytometry assay for detecting apoptosis
All flow cytometry assays were performed within one hour
after blood extraction to ensure that the results were as
close as possible to an in vivo situation. Fixed amounts of
blood were diluted 1:5 with PBS and 100 μL was stained
with 10 μL of each of the following: fluorescence conju-
gated monoclonal antibodies against CD45-phycoerythrin
(PE)-Cy5 (clone J33), CD61-fluorescein isothiocyanate
(FITC; clone SZ21), and APO 2.7-PE (clone 2.7A6A3;
Immunotech, Marseille, France), and titrated at saturating
concentrations. The CD45-PE-Cy5 antibody reacted with
the CD45 family of trans-membrane glycoproteins, which
were expressed on the surface of all human leukocytes and
were pan-leukocyte markers. The CD61-FITC antibody
was a pan-platelet marker that reacted with the GPIIb/IIIa
complex (fibrinogen receptor). The APO 2.7-PE antibody
reacted with a 38-kDa mitochondrial membrane protein
(7A6 antigen), which was detectable in non-permeabilized
cells in the late apoptotic state [23].
Annexin V staining, relevant to early apoptosis, pro-
duced similar results but was rejected for questionable
reliability under fixation conditions, with formaldehyde
clearly biasing the staining results. Mouse immunoglobu-
lin G-PE was a control for non-specific staining, which
did not differ from the APO2.7-PE signal on platelets,
such that each subject was used as its own control without
changing the sample tube. After 30 minutes of incubation
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diluted with 0.5 ml of FACSFlow (Becton Dickinson, San
Jose, CA).
Flow cytometry analysis was performed immediately
after staining using an Epics XL flow cytometer (Beckman
Coulter, Fullerton, Calif) and CellQuest software. Five
thousand CD45-PE-Cy5+ cells per sample were acquired
in a combined forward and side scatters and deep-red
FL4 fluorescence (CD45-PE-Cy5) leukocyte gate. Another
5000 CD61-FITC + cells per sample were acquired in a
combined forward and side scatters and green FL1 fluor-
escence (CD61-FITC) platelet gate to define a negative
control threshold for the measurement of apoptosis. Each
subject was his/her own control.
Membrane phosphatidyl-serine was detected by annexin-
V using a commercially available kit (Boehringer Mannheim,
Indianapolis, Ind). The PBS-washed leucocytes were incu-
bated with annexin V-FITC and 7-amino-actinomycin D
(7-AAD) for 15 min at room temperature according to
the manufacturer’s guidelines. Samples were transferred to
5 mL polypropylene tubes, diluted with 900 μL Hanks’
balanced salt solution, and placed on ice before analysis by
flow cytometry. The samples were analyzed using an Epics
XL flow cytometer (Beckman Coulter, Fullerton, CA) and
CellQuest software. Fifteen thousand events were counted
per sample. Low-fluorescence debris was gated-out of the
analysis. Leukocyte subtypes were identified according to
their CD45 expression intensity and divided into neutro-
phils, monocytes, and lymphocytes.
Annexin V-FITC staining was identified in fluorescent-1
and 7-AAD staining in fluorescent-4. The cells were iden-
tified as follows: early apoptotic cells if they were positive
for marker annexin V-FITC but negative for 7-AAD; late
apoptotic cells if they were positive for annexin V-FITC
and 7-AAD; dead cells if they were negative for annexin
V-FITC but positive for 7-AAD; and viable cells if they
were negative for annexin V-FITC and 7-AAD.
Fixed amounts of blood were diluted 1:5 with PBS, while
100 μL was stained with 10 μL of each of the following:
fluorescence conjugated monoclonal antibodies against
CD4-phycoerythrin (PE)-Cy5, CD19-fluorescein isothio-
cyanate (FITC), and CD8- phycoerythrin (PE). After each
of the above staining, further staining was done with
annexin V-FITC, 7-amino-actinomycin D (7-AAD), or APO
2.7-PE (clone 2.7A6A3; Immunotech, Marseille, France),
with titration at saturating concentrations. The samples
were then transferred to 5 mL polypropylene tubes,
diluted with 900 μL Hanks’ balanced salt solution, and
placed on ice before flow cytometry.
The samples were analyzed using an Epics XL flow cyt-
ometer (Beckman Coulter, Fullerton, Calif) and CellQuest
software. Fifteen thousand events were counted per
sample. Lymphocyte subtypes were identified according
to their surface antigen (i.e., CD4+, CD8+, or CD19+)expression intensity. A database coordinator was respon-
sible for monitoring all data collection and entry.
Western blot analysis
Peripheral blood mononuclear cell (PBMC) intracellular
protein levels of caspase-9, caspase-9c, caspase-10, caspase-
10-c, and pIRF7 were detected by Western blot method.
The PBMCs were separated by Ficoll-Paque (GE Health-
care Bio-Sciences AB, Stockholm, Sweden) density gradi-
ent centrifugation. The PBMC protein was extracted with
RIPA Buffer containing 1 mmol/L protease inhibitor and
1 mmol/L phosphatase inhibitor. Proteins with sample
buffer were then boiled for 10 min and aliquots of the
supernatants (40 μg/lane) were fractionated by electro-
phoresis in 10% SDS acrylamide gel, electro-transferred to
PVDF membranes, and blocked with 5% non-fat pow-
dered milk in TBS-T (20 mmol/L Tris-base [pH 7.6],
137 mmol/L NaCl, 0.5% Tween-20).
The membranes were then incubated with commercially
available rabbit polyclonal antibodies recognizing caspase-9
(Cell signaling, #9501), phospho-IRF-7 (Cell signaling,
#5184), rat polyclonal antibodies recognizing caspase-10
(Biolegend, #645202) at 4°C overnight. Following exten-
sive washing with TBS-T, the blots were incubated for
60 min with secondary antibodies. After brief rinsing
with TBS-T, immuno-reactive protein bands were vi-
sualized by a chemiluminescence-based procedure using
the ECL detection kit (Thermo, SuperSignal West Femto
Maximum Sensitivity Substrate) according to the manu-
facturer’s instructions. The signal was quantified densito-
metrically by Quantity One 1-D analysis software (Bio-Rad
USA, Life Science Research, Hercules, CA).
Activated caspase-9 was demonstrated by cleaved
caspase-9 (active caspase-9, caspase-9c, 37 kd) from original
caspase-9 (caspase-9, 47 kd) [18]. Activated caspase-10 was
demonstrated by cleaved caspase-10 (active caspase-10,
caspase-10c, 43 kd) from original caspase-10 (caspase-10,
59 kd) [19].
Determination of intracellular protein concentration by
enzyme linked-immuno-sorbent assay (ELISA)
Intracellular protein levels and serum levels of MDA5
were detected by commercial ELISA kit. Aliquots of the
supernatants of protein (40 μg) were tested using a com-
mercial ELISA kit to determine the concentration of intra-
cellular MDA5 (APOtech, #APO-54 N-035, Epalinges,
Switzerland). A commercial ELISA kit was used to de-
termine the concentration of serum MDA5 (Cusabio,
CSB-EL011017HU, China).
Statistical analysis
Data were expressed as mean ± SD or median (inter-quar-
tile range). Categorical variables were compared using
Chi-square test or Fisher’s exact test, as appropriate.
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and intracellular protein levels) were square root trans-
formed to improve normality, and then compared be-
tween two groups using Student’s t-test and among three
groups using one-way analysis of variance (ANOVA). Cor-
relation analysis was used to explore the relationshipTable 1 Demographic data of SLE patients and healthy contro
Healthy controls (n = 18
Age (y) (mean ± SD) 43.78 ± 10.90
Male/female 5/13
Peripheral blood studies
Leukocytes (×1000/ml) 5.85 ± 2.15
% granulocyte 61.60 ± 12.76
% lymphocyte 31.01 ± 10.85
% monocyte 5.63 ± 1.74
Hemoglobin (mg/dL) 13.32 ± 1.77
Platelet counts (×10000/ml) 23.19 ± 6.82
c3 level (median, IQR) ND
c4 Level (median, IQR) ND
a-dsDNA (median, IQR) ND
a-rib p (median, IQR) ND
SLEDAI score ( median, IQR) ND
Medication used during at blood test
Equivalent prednisolone dose per day (mg)
Immune modulators except steroid (number)
Leukocyte Apoptosis by flow cytometry
Leukocyte apoptosis (%)
Annexin V (%) 10.7 (8.9, 13.8)
APO2.7 (%) 0.7 (0.5, 0.9)
Annexin V + 7AAD (%) 3.34 (2.85, 4.78)
Neutrophil apoptosis (%)
Annexin V (%) 14.5 (10.0, 16.7)
APO2.7 (%) 0.51 (0.39, 0.62)
Annexin V + 7AAD (%) 3.7 (2.1, 7.6)
Lymphocyte apoptosis (%)
Annexin V (%) 4.85 (4.01, 7.26)
APO2.7 (%) 0.34 (0.22, 0.45)
Annexin V + 7AAD (%) 1.76 (1.17, 2.40)
Monocyte apoptosis (%)
Annexin V (%) 16.7 (13.0, 21.8)
APO2.7 (%) 1.7 (1.05, 2.44)
Annexin V + 7AAD (%) 5.5 (4.2, 6.6)
Abbreviations: SLE, systemic lupus erythematosus; IQR, inter-quartile range.
Data presented with median (IQR) or mean ± SD.
Continuous variables among three groups were compared using one-way ANOVA (ana
Comparison between the three groups with non-normalized distributed parameters
Mann-Whitney U test.
*p < 0.05.between the mean steroid dosages and mean SLEDAI
score, and variables such as surface markers of leukocytes,
and intracellular protein levels. Statistical significance was
set at p < 0.05. All statistical calculations were performed
using the SAS software package, version 9.1 (2002, SAS
Statistical Institute, North Carolina).ls
) SLE patients (n = 35) Disease control (n = 15) p value
40.24 ± 11.78 47.53 ± 11.06 0.17
3/32 1/13 0.92
6.35 ± 2.61 7.92 ± 3.11 0.12
67.89 ± 12.63 72.36 ± 16.25 0.25
23.65 ± 10.87 20.46 ± 14.77 0.18
6.14 ± 2.71 4.63 ± 2.10 0.48
11.73 ± 1.73 12.52 ± 1.58 <0.01*
22.19 ± 8.91 23.05 ± 8.60 0.93
91.0 (61.4, 107.5) ND
19.30 (9.2, 24.) ND
13.4 (1.78, 67) ND
0.10 (0.1, 18) ND
6 (4,12) ND
0 (0,8.75) 0 (0,8.75) 0.90
1 (1,1) 1 (1, 1.25) 0.48
11.9 (8.6, 17.1) 12.1 (9.3, 20.6) 0.41
1.3 (0.9, 2.0) 1.17 (0.9, 2.1) <0.01*
6.34 (3.7, 9.7) 7.06 (5.16, 13.95) <0.01*
19.4 (11.5, 29.8) 18.9 (14.4, 28.5) 0.08
0.57 (0.41, 1.6) 0.82 (0.35, 1.39) 0.18
8.6 (2.7, 19.2) 15.94 (10.9, 31.4) <0.01*
6.28 (4.18, 9.52) 6.97 (4.00, 12.47) 0.16
0.67 (0.4, 0.8) 0.79 (0.60, 1.01) <0.01*
2.12 (1.31, 2.87) 2.20 (1.22, 3.54) 0.49
16.4 (10.9, 22.1) 18.2(14.0, 23.9) 0.65
2.8 (1.9, 5.2) 2.3 (1.3, 4.6) 0.02*
8.0 (4.3, 14.4) 8.2 (4.5, 17.0) 0.07
lysis of variance) between healthy group, SLE, and diseases control.
was calculated using the Kruskal-Wallis test, while post-hoc analysis was by
Table 2 Correlation analysis between leukocyte apoptosis
markers and disease activity and steroid dosage in





r p r p
CD4+ cell Annexin V (%) 0.02 0.93 0.01 0.96
CD4+ cell Annexin V + 7AAD (%) -0.09 0.70 -0.33 0.12
CD8+ cell Annexin V (%) -0.30 0.19 -0.17 0.45
CD8+ cell Annexin V + 7AAD (%) -0.06 0.79 -0.19 0.39
CD19+ cell Annexin V (%) 0.17 0.46 -0.19 0.39
CD19+ cell Annexin V + 7AAD (%) 0.12 0.61 -0.15 0.50
Monocyte Annexin V (%) 0.01 0.97 -0.11 0.54
Monocyte Annexin V + 7AAD (%) 0.04 0.85 -0.14 0.46
APO2.7 CD4+ cell (%) 0.17 0.51 -0.29 0.20
APO2.7 CD8+ cell (%) 0.32 0.19 -0.12 0.61
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Baseline characteristics of the study patients
The baseline characteristics, laboratory data, and apop-
tosis markers of the SLE patients, diseases controls, and
healthy controls were listed in Table 1. The 15 diseases
control patients included ten with Sjogren’s syndrome,
two with rheumatoid arthritis, two with vasculitis, and
one with Behcet’s disease. The clinical symptoms of the
35 SLE patients included neurologic involvement in 15,
musculo-skeletal involvement in 10, hematologic involve-
ment in seven, renal involvement in five, cardio-respiratory
involvement in three, and muco-cutaneous involvement in
three. Ten SLE patients had more than one organ involve-
ment. There was no significant difference in age and sex
among the three groups. The mean dosages of steroids and
the number of immune-modifying medication were similar
between the SLE and disease control groups (p > 0.05)
(Table 1).APO2.7 CD19+ cell (%) 0.59 0.01* 0.17 0.46
APO2.7 monocyte (%) 0.05 0.77 -0.17 0.35
Abbreviations: r, correlation coefficient; p, p value; SLEDAI, Systemic lupus
erythematosus disease activity index 2000.
*p < 0.05.Leukocyte apoptosis in patients with SLE and the controls
The laboratory data and percentage of leukocyte apop-
tosis among the three groups were also listed in Table 1.
Except for hemoglobin level, all of the cell counts were
not significantly different. Nonetheless, the SLE patients
had higher apoptosis markers, including higher APO2.7
(p < 0.0001) and late apoptosis markers (p = 0.0019) in
leukocytes. There were higher late apoptosis markers
among neutrophils (p= 0.0479), higher APO2.7 apoptosis
markers among monocytes (p= 0.0018), and higher APO2.7
apoptosis markers among lymphocytes (p = 0.0004)
(Table 1).Correlation between clinical severity and percentage of
monocytes and lymphocyte apoptosis
Correlation analysis was used to test the influence of
leukocyte apoptosis on SLEDAI disease activity. The
statistical results (correlation coefficient, p value) re-
vealed that only the percentage of APO2.7 on CD19+ cells
was positively associated with disease activity (r = 0.59,
p = 0.01) (Table 2). The other subsets of leukocyte apop-
tosis were not correlated with SLEDAI disease activity.
Further exploring the relationship between percentage of
APO2.7 of CD19+ cell apoptosis and levels of autoanti-
bodies revealed no correlation. Specifically, percentage
of APO2.7 of CD19+ cell apoptosis did not correlate
with the level of anti-Ro52 (r = 0.35, p = 0.39), anti-
Ro60 (r = 0.29, p = 0.48), anti-La (r = 0.23, p = 0.34),
anti-RNP (r = 0.01, p = 0.99), anti-Sm (r = 0.41, p = 0.11),
anti-dsDNA (r = -0.28, p = 0.22), C3 (r = -0.16, p = 0.49), or
C4 (r = 0.01, p = 0.98). Lastly, there was no significant rela-
tionship between the percentage of each apoptosis marker
(e.g., Annexin V, APO2.7, annexin V + 7AAD) and steroid
dosage in the SLE patients (all p > 0.05) (Table 2).Correlation between each intracellular protein level and
disease activity in SLE patients
The intracellular proteins, including active cleaved cas-
pase 10c (43 kD), caspase 9c (37 kD), active MAVS
(57 kD), and pIRF7 (65 kD) were determined by Western
blot method (Figure 2a), while MDA5 levels were de-
termined by ELISA (Figure 2b). The correlation be-
tween each intracellular protein, including MDA5,
active cleaved caspase-9, active cleaved caspase-10,
pIRF7, and active MAVS revealed that active cleaved
caspase-9 and active MAVS level both negatively cor-
related with SLEDAI (p = 0.01 and p < 0.05, respect-
ively) (Table 3).
Active cleaved caspase-9 positively correlated with ac-
tive cleaved caspase-10 (p < 0.01). Both the active cleaved
caspase-9 and caspase-10 positively correlated with pIRF7
(p < 0.01). Despite the absence of correlation between
MDA5 level and other molecules, activated MAVS
positively correlated with the active cleaved caspase-9,
caspase-10, and pIRF7 (all p < 0.01).
Correlation between original and cleaved active caspase-9
and -10 in SLE
In PBMCs, caspase-10 was positively associated with
caspase-10c (p < 0.001) (Figure 3a). Caspase-9 and cas-
pase-10 positively correlated with each other (p < 0.001)
(Figure 3b). Caspase-9 positively associated with active
cleaved casepase-9c (p < 0.001) (Figure 3c).
Figure 2 Intracellular protein concentration from peripheral blood mononuclear cells in patients with systemic lupus erythematosus
(SLE). (a) Lanes 1-7: SLE patients; Lane 8-10: disease control patients; and Lane 11: Jurkat T cell lysate. (b) MDA5 levels, detected by ELISA method,
were significantly different between SLE patients and disease controls.
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Table 3 Correlations analysis between activated caspase-9, activated caspase-10, pIRF7, virus infection markers, and
systemic lupus erythematosus disease activity
SLEDAI activated caspase 9 activated caspase 10 pIRF7 activated MAVS MDA5
SLEDAI r 1.00 -0.47* -0.31 -0.31 -0.36* -0.03
p X 0.01* 0.13 0.09 <0.05* 0.90
activated caspase 9 r 1.00 0.81* 0.83* 0.88* 0.39
p X <0.01* <0.01* <0.01* 0.06
activated caspase 10 r 1.00 0.91* 0.85* 0.23
p X <0.01* <0.01* 0.33
pIRF7 r 1.00 0.84* 0.14
p X <0.01* 0.51




Abbreviations: r, correlation coefficient; p, p value; SLEDAI, Systemic lupus erythematosus disease activity index 2000; pIRF7, phosphorylated interferon regulator
factor 7; MAVS, mitochondrial antiviral signaling protein; MDA5, Melanoma Differentiation-Associated protein 5.
*p < 0.05.
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level in SLE
The negative coefficient between MAVS and SLE disease
activity (Table 3) was enhanced if patients with lower
MDA5 levels (cut-off value, 366 pg/mL, mean of disease
controls) were removed (Figure 4). The p value changed
from 0.04955 to 0.01123, indicating that SLE was a het-
erogeneous group and could be divided into at least two
subgroups according to MDA5 levels. Disease activity
negatively correlated with MAVS in the high MDA5 level
SLE patients (p < 0.05) but not in the low MDA5 level SLE
patients (p = 0.67) (data not shown).
Discussion
The present study has several major findings. First, there
are comparable apoptosis markers between SLE and dis-
ease control patients, even though only neutrophil late
apoptosis is statistically significantly higher in disease con-
trols than in SLE patients (p < 0.05) (Table 1). Second, SLE
disease activity is positively associated with CD19+ cell
APO 2.7 marker level (Table 2), but negatively associated
with MAVS and caspase-9 levels (Table 3) (p < 0.05).
Third, although most of the surface markers of apoptosis
are not significantly different between SLE and disease
controls, the levels of intracellular molecules are signifi-
cantly different (p < 0.05) (Table 4). Fifth, markers of viral
infection and anti-virus transcription factors, including
MDA5, MAVS, and pIRF7, are significantly higher in SLE
patients than in disease controls (p < 0.05) (Table 4). Sixth,
caspase-9 and caspase-10 levels are positively correlated
with anti-virus factors like MAVS and pIRF7 (p < 0.05)
(Table 3), but not MDA5 levels. Lastly, SLE disease activity
is more negatively associated with MAVS among patients
with high MDA5 levels (Figure 3).This present study confirms that pronounced apoptosis
in SLE and disease activity is positively associated with
APO2.7 of CD19+ cells [2]. Disease activity is also nega-
tively associated with caspase-9 and MAVS in PBMCs
(Table 3). These all point to a mitochondrial pathway. The
explanation may be that when disease activity increases,
the PBMCs are activated and anti-apoptotic molecules ac-
cumulate on the mitochondrial membrane [24-27], which
suppress caspase-9. Moreover, another article mentions
that the expression of caspase 9 is decreased in female
SLE patients [20]. Active cleaved caspase-9 may come
from any lineage of PBMCs, such as activation-induced-
cell-death of γδ-T cell, which depends on caspase-9 [28],
or through pathways not dependent on caspase in other
CD4+ T cells [29].
During disease flare-up, CD19+ cells are prone to produ-
cing more autoantibodies with mitochondrial activation,
which may lead to APO2.7-related apoptosis. However, the
detailed apoptosis mechanism remains unknown. On the
other hand, the reason that caspase-10 is not correlated
with disease activity may be that there are too many con-
founding factors affecting the extrinsic apoptosis pathway,
like TNF-α [30] and other stress signaling [31].
The negative correlation between disease activity and
MAVS is contrary to a previous clinical observation [9].
Thus, the role of MDA5 in this correlation has been
investigated by determining the levels of MDA5 among
SLE and disease control patients. A previous study com-
paring MDA5 levels between SLE and healthy controls
[32] shows the MDA5 is significantly higher in SLE than
in healthy patients. In the present study, MDA5 levels,
as well as the anti-virus signaling proteins MAVS and
pIRF7, are significantly higher in SLE than in disease con-
trol patients (Table 4). This indicates that SLE patients are
Figure 3 Correlations between original and cleaved caspase-9
and caspase-10 in systemic lupus erythematosus patients. (a) In
PBMCs, original caspase-10 was positively associated with active
cleaved casepase-10c (p < 0.05). (b) Original caspase-10 was positively
associated with original caspase-9 (p < 0.05). (c) Original caspase-9 was
positively associated with active cleaved casepase-9 (p < 0.05).
Abbreviations: r, correlation coefficient.
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Furthermore, using the mean MDA5 level from dis-
ease controls as reference, disease activity is negatively
correlated to MAVS in SLE patients with high MDA5
levels (p < 0.05), but not in those with low MDA5 levels
(p = 0.67) (Figure 4). This indicates that MAVS is only
negatively associated with disease activity in a subset of
SLE patients. Further studies to determine the specific
role of MDA5 and MAVS in SLE are needed.
The three major IRFs (i.e., IRF3, IRF5, and IRF7) are
downstream of mitochondrial signaling to promote
interferon-stimulated gene expression [33,34]. According
to a previous study, SLE is an interferon-associated dis-
ease. Thus, this study focused on interferon regulating
factors, particularly on IRF7 because of a previous study
by Becker et al. [31], wherein IRF7 is the only one signifi-
cantly different between healthy and SLE CD19+ cells. In
the current study, SLE CD19+ cells are associated with
disease activity in SLE patients.
Caspase-9 is mainly an intracellular initiator caspase
and is related to extrinsic apoptosis from dependent re-
ceptors [3]. In the current study, caspase-9c is positively
associated with MAVS and pIRF7 (Table 3). It will be in-
teresting to elucidate the relationship between viral infec-
tion and caspase-9 activation, since virus-related cellular
apoptosis has been demonstrated in some HIV infected
patients [35], while caspase-9 activation is noted in chronic
hepatitis C viral infection [36]. Caspase-9c and MAVS are
both negatively associated with disease activity in this study
(Table 3), which may hint that activation-induced-cell-
death through mitochondrial pathway is different from
the virus-related apoptosis and/or activation pathway in
SLE patients. Virus could lead to IRF7 down-regulation
[37] or activation [13,38,39]. Virus-related activation and
activation-induced apoptosis of mononuclear cells in SLE
through the mitochondrial pathway may exist but war-
rants further study.
There are several positive correlations between caspase-
10c and MAVS, as well as caspase-10c and pIRF7 (Table 3).
These indicate that caspase-10, like caspase-9, may be
another major initiator of the caspase pathway in PBMCs
in SLE. Caspase-10c is produced mainly after caspase-10 is
activated and cleaved. Its molecular weight is around
43 kD [40]. Both the original caspase-10 (59 kD) and
caspase-10c (43 kD) have the large protease subunit p20,
Figure 4 Correlation between MAVS and SLEDAI. (a) Origin correlation between MAVS and SLEDAI. (b) Correlation between MAVS and SLEDAI
after eliminating the low-MDA5 sub-group.
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Table 4 Comparison of intracellular molecules between patients with systemic lupus erythematosus and disease controls
SLE Disease controls
n = 31 n = 15 p value
Intracellular protein levels
MDA5 (pg/mL) 701.53 (543.45,885.96) 296.74 (216.50,567.40) <0.01*
Activated caspase 9 9.74 (0.81, 22.34) 2.20 (0.26, 3.58) 0.06
Activated caspase 10 0.77 (0.51, 2.09) 0.15 (0.04, 0.24) <0.01*
pIRF7 0.10 (0.04, 0.30) 0.03 (0.01, 0.04) <0.01*
Activated MAVS 0.82 (0.19, 2.59) 0.24 (0.11, 0.42) 0.02*
Data presented with median, IQR; IQR, inter-quartile range.
The levels of pIRF7, activated caspase 9, caspase 10, and MAVS from Western blot method were normalized with actin levels.
Abbreviation: pIRF7, phosphorylated interferon regulator factor 7; MAVS, mitochondrial anti-viral signaling protein.
*p < 0.05.
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Both molecules are functionally active [40].
Nonetheless, this study has several limitations. First,
theoretically, it would have been better if PBMCs were
divided into different cell lineages. In this study, as in
other studies, PBMCs are used as a surrogate rather
than lymphocytes only because of the technical difficulty
to differentiate lymphocytes from monocytes using flow
cytometry study [41,42]. Because lymphocytes account
for the majority of PMBCs, the results are not much
different from the true state. Second, this is a cross-
sectional observational study. Theoretically, immuno-
suppressant drugs can affect leukocyte activity and
autoantibody levels even if SLE patients are in the con-
valescent stage. Lastly, the case number in this study is
small. Large-scale prospective and longitudinal studies
are needed to evaluate the prognostic contribution of
leukocyte apoptosis on clinical outcome.
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